Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) rose 11% during mid-day trading on Tuesday. The company traded as high as C$0.46 and last traded at C$0.46. 236,408 shares traded hands during mid-day trading, an increase of 174% from the average daily volume of 86,229 shares. The stock had previously closed at C$0.41.
Medicenna Therapeutics Trading Up 13.4%
The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65. The firm’s 50 day moving average price is C$0.42 and its 200 day moving average price is C$0.47. The stock has a market capitalization of C$42.92 million, a P/E ratio of -2.11 and a beta of 2.93.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Featured Stories
- Five stocks we like better than Medicenna Therapeutics
- Record French Debt Could Create Opportunities for U.S. Market Operators
- InvenTrust’s Sell-Off Opens a Potential Entry Point
- Curaleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
- Why onsemi’s Synaptics Pivot Could Be a Game Changer
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
